EGFR and colorectal carcinoma: The authors mentioned that right-sided tumors usually respond only to immunotherapies due to their high antigenic load [39]; however, as addressed by others, despite no benefit in OS has been demonstrated, available data can endorse the use of an anti-epidermal growth factor receptor (anti-EGFR) treatment in right-sided RAS (retrovirus-associated DNA sequence) wild-type advanced CRC in tumor shrinkage [43].